Takeda Pharmaceutical Co ADR (NYSE: TAK)’s stock price has plunge by 0.54relation to previous closing price of 14.90. Nevertheless, the company has seen a -0.27% plunge in its stock price over the last five trading sessions. seekingalpha.com reported 2025-04-01 that Takeda’s AI-powered “returning to growth” program has improved profit margins, leading to upgraded FY2024 guidance and a JPY100 billion share buyback program. Takeda’s Rusfertide and Protagonist’s Icotrokinra show strong Phase III results, with potential regulatory approvals and launches by 2026, boosting revenue prospects. Protagonist’s financial stability, with a cash runway until 2028, supports a “Strong Buy” rating for high-risk tolerant investors.
Is It Worth Investing in Takeda Pharmaceutical Co ADR (NYSE: TAK) Right Now?
The price-to-earnings ratio for Takeda Pharmaceutical Co ADR (NYSE: TAK) is above average at 35.23x, Company’s 36-month beta value is 0.29.Analysts have differing opinions on the stock, with 3 analysts rating it as a “buy,” 0 as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for TAK is 3.17B, and currently, short sellers hold a 0.14% ratio of that floaft. The average trading volume of TAK on April 03, 2025 was 1.75M shares.
TAK’s Market Performance
TAK stock saw an increase of -0.27% in the past week, with a monthly gain of 1.01% and a quarterly increase of 13.74%. The volatility ratio for the week is 1.28%, and the volatility levels for the last 30 days are 1.13% for Takeda Pharmaceutical Co ADR (TAK). The simple moving average for the past 20 days is -0.44% for TAK’s stock, with a 7.53% simple moving average for the past 200 days.
Analysts’ Opinion of TAK
BofA Securities, on the other hand, stated in their research note that they expect to see TAK reach a price target of $20. The rating they have provided for TAK stocks is “Buy” according to the report published on March 16th, 2023.
Cowen gave a rating of “Outperform” to TAK, setting the target price at $24 in the report published on July 19th of the previous year.
TAK Trading at 5.05% from the 50-Day Moving Average
After a stumble in the market that brought TAK to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -2.12% of loss for the given period.
Volatility was left at 1.13%, however, over the last 30 days, the volatility rate increased by 1.28%, as shares sank -0.40% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +14.35% upper at present.
During the last 5 trading sessions, TAK fell by -0.27%, which changed the moving average for the period of 200-days by +14.53% in comparison to the 20-day moving average, which settled at $15.05. In addition, Takeda Pharmaceutical Co ADR saw 13.14% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at TAK starting from Giles Richard Platford, who proposed sale 19,073 shares at the price of $14.94 back on Aug 23 ’24. After this action, Giles Richard Platford now owns shares of Takeda Pharmaceutical Co ADR, valued at $284,951 using the latest closing price.
Stock Fundamentals for TAK
Current profitability levels for the company are sitting at:
- 0.1 for the present operating margin
- 0.55 for the gross margin
The net margin for Takeda Pharmaceutical Co ADR stands at 0.05. The total capital return value is set at 0.04. Equity return is now at value 2.87, with 1.38 for asset returns.
Based on Takeda Pharmaceutical Co ADR (TAK), the company’s capital structure generated 0.39 points at debt to capital in total, while cash flow to debt ratio is standing at 0.22. The debt to equity ratio resting at 0.65. The interest coverage ratio of the stock is 2.28.
Currently, EBITDA for the company is 874.6 billion with net debt to EBITDA at 3.63. When we switch over and look at the enterprise to sales, we see a ratio of 2.51. The receivables turnover for the company is 6.23for trailing twelve months and the total asset turnover is 0.3. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.31.
Conclusion
In a nutshell, Takeda Pharmaceutical Co ADR (TAK) has experienced a better performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
